Precise Correction of Disease Mutations in Induced Pluripotent Stem Cells Derived From Patients With Limb Girdle Muscular Dystrophy.
Limb girdle muscular dystrophies types 2B (LGMD2B) and 2D (LGMD2D) are degenerative muscle diseases caused by mutations in the dysferlin and alpha sarcoglycan genes, respectively. Using patient derived induced pluripotent stem cells (iPSC) we corrected the dysferlin nonsense mutation c.5713C>T; p.R1905X and the most common alpha sarcoglycan mutation, missense c.229C>T; p.R77C, by single stranded oligonucleotide mediated gene editing, using the CRISPR/Cas9 gene editing system to enhance the frequency of homology directed repair. We demonstrated seamless, allele specific correction at efficiencies of 0.7 1.5% As an alternative, we also carried out precise gene addition strategies for correction of the LGMD2B iPSC by integration of wild type dysferlin cDNA into the H11 safe harbor locus on chromosome 22, using dual integrase cassette exchange (DICE) or TALEN assisted homologous recombination for insertion precise (THRIP) These methods employed TALENs and homologous recombination, and DICE also utilized site specific recombinases. With DICE and THRIP, we obtained targeting efficiencies after selection of ~20% We purified iPSC corrected by all methods and verified rescue of appropriate levels of dysferlin and alpha sarcoglycan protein expression and correct localization, as shown by immunoblot and immunocytochemistry. In summary, we demonstrate for the first time precise correction of LGMD iPSC and validation of expression, opening the possibility of cell therapy utilizing these corrected iPSC.
Molecular therapy the journal of the American Society of Gene Therapy